A phase II, randomized, double-blind, placebo-controlled multicenter trial of endostar in patients with metastatic melanoma

Molecular Therapy

Volumn 21, Issue 7, 2013, Pages 1456-1463

  Cui, Chuanliang ^a   Mao, Lili ^a   Chi, Zhihong ^a   Si, Lu ^a   Sheng, Xinan ^a   Kong, Yan ^a   Li, Siming ^a   Lian, Bin ^a   Gu, Kangsheng ^b   Tao, Min ^c   Song, Xin ^d   Lin, Tongyu ^e   Ren, Xiubao ^f   Qin, Shukui ^g   Guo, Jun ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^b ANHUI MEDICAL UNIVERSITY   (China)

^c THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^d KUNMING MEDICAL UNIVERSITY   (China)

^e SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^f TIANJIN MEDICAL UNIVERSITY   (China)

^g PLA Cancer Centre   (China)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; DACARBAZINE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLACEBO; RECOMBINANT ENDOSTATIN;

ABDOMINAL DISTENSION; ADULT; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLURRED VISION; CHEST TIGHTNESS; CONSTIPATION; CONTROLLED STUDY; DISORIENTATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHROPENIA; FATIGUE; FEMALE; FEVER; GENE MUTATION; HEMATURIA; HUMAN; HYPOKALEMIA; LEG EDEMA; LEUKOCYTOSIS; LEUKOCYTURIA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; MULTICENTER STUDY; NAUSEA; ONCOGENE C KIT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RASH; SALIVATION; SIDE EFFECT; SKIN PAIN; ST SEGMENT; THROMBOCYTOPENIA; UREA NITROGEN BLOOD LEVEL; VOMITING;

EID: 84879695443     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.79     Document Type: Article

References (48)

1. Falkson, CI, Ibrahim, J, Kirkwood, JM, Coates, AS, Atkins, MB and Blum, RH (1998). Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 16: 1743-1751.
2. Middleton, MR, Grob, JJ, Aaronson, N, Fierlbeck, G, Tilgen, W, Seiter, S et al. (2000). Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18: 158-166. (Pubitemid 30036349)
3. Avril, MF, Aamdal, S, Grob, JJ, Hauschild, A, Mohr, P, Bonerandi, JJ et al. (2004). Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 22: 1118-1125. (Pubitemid 41095046)
4. Seetharamu, N, Ott, PA and Pavlick, AC (2009). Novel therapeutics for melanoma. Expert Rev Anticancer Ther 9: 839-849.
5. Sosman, JA, Kim, KB, Schuchter, L, Gonzalez, R, Pavlick, AC, Weber, JS et al. (2012). Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366: 707-714.
6. Hodi, FS, O'Day, SJ, McDermott, DF, Weber, RW, Sosman, JA, Haanen, JB et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711-723.
7. Birck, A, Kirkin, AF, Zeuthen, J and Hou-Jensen, K (1999). Expression of basic fbroblast growth factor and vascular endothelial growth factor in primary and metastatic melanoma from the same patients. Melanoma Res 9: 375-381. (Pubitemid 29407070)
8. Ugurel, S, Rappl, G, Tilgen, W and Reinhold, U (2001). Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 19: 577-583. (Pubitemid 32112873)
9. Ellis, LM and Hicklin, DJ (2008). VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 8: 579-591.
10. Hurwitz, H, Fehrenbacher, L, Novotny, W, Cartwright, T, Hainsworth, J, Heim, W et al. (2004). Bevacizumab plus irinotecan, fuorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342. (Pubitemid 38702844)
11. Miller, K, Wang, M, Gralow, J, Dickler, M, Cobleigh, M, Perez, EA et al. (2007). Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357: 2666-2676.
12. Sandler, A, Gray, R, Perry, MC, Brahmer, J, Schiller, JH, Dowlati, A et al. (2006). Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355: 2542-2550. (Pubitemid 44917502)
13. Lai, A, Tran, A, Nghiemphu, PL, Pope, WB, Solis, OE, Selch, M et al. (2011). Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 29: 142-148.
14. Rini, BI, Halabi, S, Rosenberg, JE, Stadler, WM, Vaena, DA, Archer, L et al. (2010). Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: fnal results of CALGB 90206. J Clin Oncol 28: 2137-2143.
15. Perren, TJ, Swart, AM, Pfsterer, J, Ledermann, JA, Pujade-Lauraine, E, Kristensen, G et al.; ICON7 Investigators. (2011). A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365: 2484-2496.
16. Kelly, WK, Halabi, S, Carducci, M, George, D, Mahoney, JF, Stadler, WM et al. (2012). Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol 30: 1534-1540.
17. Kim, KB, Sosman, JA, Fruehauf, J P, Linette, G P, Markovic, SN, McDermott, DF et al. (2012). BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol 30: 34-41.
18. Grignol, V P, Olencki, T, Relekar, K, Taylor, C, Kibler, A, Kefauver, C et al. (2011). A phase 2 trial of bevacizumab and high-dose interferon alpha 2B in metastatic melanoma. J Immunother 34: 509-515.
19. von Moos, R, Seifert, B, Simcock, M, Goldinger, SM, Gillessen, S, Ochsenbein, A et al.; Swiss Group for Clinical Cancer Research (SAKK). (2012). First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07). Ann Oncol 23: 531-536.
20. Vihinen, P P, Hernberg, M, Vuoristo, MS, Tyynelä, K, Laukka, M, Lundin, J et al. (2010). A phase II trial of bevacizumab with dacarbazine and daily low-dose interferon-alpha2a as frst line treatment in metastatic melanoma. Melanoma Res 20: 318-325.
21. Varker, KA, Biber, JE, Kefauver, C, Jensen, R, Lehman, A, Young, D et al. (2007). A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann Surg Oncol 14: 2367-2376. (Pubitemid 47174913)
22. O'Reilly, MS, Boehm, T, Shing, Y, Fukai, N, Vasios, G, Lane, WS et al. (1997). Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285. (Pubitemid 28015876)
23. Yoon, SS, Eto, H, Lin, CM, Nakamura, H, Pawlik, TM, Song, SU et al. (1999). Mouse endostatin inhibits the formation of lung and liver metastases. Cancer Res 59: 6251-6256. (Pubitemid 30035650)
24. Yokoyama, Y, Dhanabal, M, Griffoen, AW, Sukhatme, VP and Ramakrishnan, S (2000). Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth. Cancer Res 60: 2190-2196. (Pubitemid 30225182)
25. Kim, YM, Jang, JW, Lee, OH, Yeon, J, Choi, EY, Kim, KW et al. (2000). Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. Cancer Res 60: 5410-5413.
26. Boehm, T, Folkman, J, Browder, T and O'Reilly, MS (1997). Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390: 404-407. (Pubitemid 28027321)
27. Mendoza, L, Valcárcel, M, Carrascal, T, Egilegor, E, Salado, C, Sim, BK et al. (2004). Inhibition of cytokine-induced microvascular arrest of tumor cells by recombinant endostatin prevents experimental hepatic melanoma metastasis. Cancer Res 64: 304-310. (Pubitemid 38114111)
28. Sund, M, Hamano, Y, Sugimoto, H, Sudhakar, A, Soubasakos, M, Yerramalla, U et al. (2005). Function of endogenous inhibitors of angiogenesis as endothelium-specifc tumor suppressors. Proc Natl Acad Sci USA 102: 2934-2939. (Pubitemid 40299894)
29. Eder, JP Jr, Supko, JG, Clark, JW, Puchalski, TA, Garcia-Carbonero, R, Ryan, DP et al. (2002). Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol 20: 3772-3784.
30. Herbst, RS, Hess, KR, Tran, HT, Tseng, JE, Mullani, NA, Charnsangavej, C et al. (2002). Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 20: 3792-3803.
31. Thomas, J P, Arzoomanian, RZ, Alberti, D, Marnocha, R, Lee, F, Friedl, A et al. (2003). Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 21: 223-231. (Pubitemid 46606150)
32. Moschos, SJ, Odoux, C, Land, SR, Agarwala, S, Friedland, D, Volker, KM et al. (2007). Endostatin plus interferon-alpha2b therapy for metastatic melanoma: a novel combination of antiangiogenic and immunomodulatory agents. Melanoma Res 17: 193-200. (Pubitemid 46788104)
33. Song, HF, Liu, XW, Zhang, HN, Zhu, BZ, Yuan, SJ, Liu, SY et al. (2005). Pharmacokinetics of His-tag recombinant human endostatin in Rhesus monkeys. Acta Pharmacol Sin 26: 124-128.
34. Wang, J, Sun, Y, Liu, Y, Yu, Q, Zhang, Y, Li, K et al. (2005). [Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients]. Zhongguo Fei Ai Za Zhi 8: 283-290. (Pubitemid 41206392)
35. Han, B, Xiu, Q, Wang, H, Shen, J, Gu, A, Luo, Y et al. (2011). A multicenter, randomized, double-blind, placebo-controlled study to evaluate the effcacy of paclitaxel-carboplatin alone or with endostar for advanced non-small cell lung cancer. J Thorac Oncol 6: 1104-1109.
36. Guo, J, Si, L, Kong, Y, Flaherty, KT, Xu, X, Zhu, Y et al. (2011). Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplifcation. J Clin Oncol 29: 2904-2909.
37. Carvajal, RD, Antonescu, CR, Wolchok, JD, Chapman, PB, Roman, RA, Teitcher, J et al. (2011). KIT as a therapeutic target in metastatic melanoma. JAMA 305: 2327-2334.
38. Maio, M, Mackiewicz, A, Testori, A, Trefzer, U, Ferraresi, V, Jassem, J et al.; Thymosin Melanoma Investigation Group. (2010). Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma. J Clin Oncol 28: 1780-1787.
39. McDermott, DF, Sosman, JA, Gonzalez, R, Hodi, FS, Linette, GP, Richards, J et al. (2008). Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol 26: 2178-2185.
40. Chapman, PB, Hauschild, A, Robert, C, Haanen, JB, Ascierto, P, Larkin, J et al.; BRIM-3 Study Group. (2011). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-2516.
41. Robert, C, Thomas, L, Bondarenko, I, O'Day, S, M D, JW, Garbe, C et al. (2011). Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364: 2517-2526.
42. Huncharek, M, Caubet, JF and McGarry, R (2001). Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials. Melanoma Res 11: 75-81. (Pubitemid 32158188)
43. Abdollahi, A, Hlatky, L and Huber, PE (2005). Endostatin: the logic of antiangiogenic therapy. Drug Resist Updat 8: 59-74. (Pubitemid 40797957)
44. Hanai, J, Gloy, J, Karumanchi, SA, Kale, S, Tang, J, Hu, G et al. (2002). Endostatin is a potential inhibitor of Wnt signaling. J Cell Biol 158: 529-539. (Pubitemid 34851711)
45. Kong, Y, Si, L, Zhu, Y, Xu, X, Corless, CL, Flaherty, KT et al. (2011). Large-scale analysis of KIT aberrations in Chinese patients with melanoma. Clin Cancer Res 17: 1684-1691.
46. Chi, Z, Li, S, Sheng, X, Si, L, Cui, C, Han, M et al. (2011). Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases. BMC Cancer 11: 85.
47. New guidelines to evaluate the response to treatment in solid tumors. (2010). J Natl Canc Inst 92: 205-216.
48. Cancer Therapy Evaluation Program (2006). Common Terminology Criteria for Adverse Events, Version 3.0. DCTO, NCI, NIH, DHHS 31 March 2003 .